Cargando…
The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritis
Apremilast is a novel agent for the treatment of inflammatory based autoimmune disorders. The objective of this study was to assess the pharmacokinetic effects of co administration of apremilast and methotrexate on both agents. This was an open-label, multi-center, 3-treatment period, sequential stu...
Autores principales: | Liu, Yong, Zhou, Simon, Nissel, James, Wu, Anfan, Lau, Henry, Palmisano, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467241/ https://www.ncbi.nlm.nih.gov/pubmed/26097790 http://dx.doi.org/10.1002/cpdd.109 |
Ejemplares similares
-
Impact of Renal Impairment on the Pharmacokinetics of Apremilast and Metabolite M12
por: Liu, Yong, et al.
Publicado: (2016) -
The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers
por: Liu, Yong, et al.
Publicado: (2014) -
Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis
por: Bulatović Ćalasan, Maja, et al.
Publicado: (2013) -
Clinical potential of apremilast in the treatment of psoriatic arthritis
por: Cauli, Alberto, et al.
Publicado: (2014) -
Pharmacokinetics and tolerability of apremilast in healthy Korean adult men
por: Huh, Ki Young, et al.
Publicado: (2021)